Diagnostic Immunohistochemistry in Tumor Metastasis

Chapter

Abstract

Immunohistochemistry (IHC) refers to the process of localizing antigens (e.g. proteins) in cells of a tissue section using antibodies that bind specifically to these antigens in bisological tissues Ramos-Vara (Vet Pathol 42:405–426, 2005). Immunohistochemical staining is widely used in the diagnosis of abnormal cells such as those found in cancerous tumors and in metastasis Webster et al. (J Histochem Cytochem 57:753–761, 2009).

Keywords

Tyrosine Leukemia Tamoxifen Imatinib Cetuximab 

References

  1. Bibeau F et al (2006) Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray. Virchows Arch 449:281–287PubMedCrossRefGoogle Scholar
  2. Buchwalow IB, Böcker W (ed) (2010) Antibodies for immunohistochemistry. SpringerLink, p 153Google Scholar
  3. Colcher D, Hand PH, Nuti M, Schlom J (1981) A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci U S A 78:3199–3203PubMedCrossRefGoogle Scholar
  4. Dällenbach P, Bonnefoi H, Pelte MF, Vlastos G (2006) Yolk sac tumours of the ovary: an update. Eur J Surg Oncol 32:1063–1075PubMedCrossRefGoogle Scholar
  5. Fernando SS, Johnson S, Bate J (1994) Immunohistochemical analysis of cutaneous malignant melanoma: comparison of S-100 protein, HMB-45 monoclonal antibody and NKI/C3 monoclonal antibody. Pathology 26:16–19PubMedCrossRefGoogle Scholar
  6. Gleissner B et al (2005) CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL). Blood 106:4054–4056PubMedCrossRefGoogle Scholar
  7. Gold JS, Dematteo RP (2006) Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg 244:176–184PubMedCrossRefGoogle Scholar
  8. Guzman G et al (2005) p53, Ki-67, and serum alpha feto-protein as predictors of hepatocellular carcinoma recurrence in liver transplant patients. Mod Pathol 18:1498–1503PubMedCrossRefGoogle Scholar
  9. Hans CP et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282PubMedCrossRefGoogle Scholar
  10. Hansen HJ et al (1974) Carcinoembryonic antigen (CEA) assay. A laboratory adjunct in the diagnosis and management of cancer. Hum Pathol 5:139–147PubMedCrossRefGoogle Scholar
  11. Harari PM (2004) Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 11:689–708PubMedCrossRefGoogle Scholar
  12. Ikeda S et al (2006) Combined immunohistochemistry of beta-catenin, cytokeratin 7, and cytokeratin 20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer. BMC Cancer 6:31Google Scholar
  13. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WDW (1994) Expression of the prostate-specific membrane antigen. Cancer Res 54:1807–1811PubMedGoogle Scholar
  14. Jorgensen JT, Nielsen KV, Ejlertsen B (2007) Pharmacodiagnostics and targeted therapies—a rational approach for individualizing medical anticancer therapy in breast cancer. Oncologist 12:397–405PubMedCrossRefGoogle Scholar
  15. Leader M, Patel J, Makin C, Henry K (1986) An analysis of the sensitivity and specificity of the cytokeratin marker CAM 5.2 for epithelial tumours. Results of a study of 203 sarcomas, 50 carcinomas and 28 malignant melanomas. Histopathology 10:1315–1324PubMedCrossRefGoogle Scholar
  16. Martignoni G et al (2004) CD10 is expressed in a subset of chromophobe renal cell carcinomas. Mod Pathol 17:1455–1463PubMedCrossRefGoogle Scholar
  17. Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 130:1466–1478PubMedGoogle Scholar
  18. Molino A. et al (1995) Estrogen receptors in 699 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat 34:221–228PubMedCrossRefGoogle Scholar
  19. Ordóñez NG (2000) Thyroid Transcription Factor-1 is a Marker of Lung and Thyroid Carcinomas. Adv Anat Pathol 7:123–127PubMedCrossRefGoogle Scholar
  20. Ramos-Vara JA (2005) Technical aspects of immunohistochemistry. Vet Pathol 42:405–426PubMedCrossRefGoogle Scholar
  21. Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS (2009) Targeting EGFR resistance networks in head and neck cancer. Cell Signal 21:1255–1268PubMedCrossRefGoogle Scholar
  22. Riddle ND, Quigley BC, Browarsky I, Bui MM (2010) Leiomyosarcoma arising in the pancreatic duct: a case report and review of the current literature. Case Report Med 2010:252–364Google Scholar
  23. Ridolfi RL, Jamehdor MR, Arber JM (2000) HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol 13:866–873PubMedCrossRefGoogle Scholar
  24. Rossi G et al (2004) TTF-1, Cytokeratin 7, 34βE12, and CD56/NCAM Immunostaining in the subclassification of large cell carcinomas of the lung. Am J Clin Pathol 122:884–893PubMedCrossRefGoogle Scholar
  25. Scartozzi M et al (2004) Epidermal Growth Factor Receptor (EGFR) Status in primary colorectal tumors does not correlate with egfr expression in related metastatic sites: implications for treatment with egfr-targeted monoclonal antibodies. J Clin Oncol 22:4772–4778PubMedCrossRefGoogle Scholar
  26. Schlom J (1986) Basic Principles and applications of monoclonal antibodies in the management of carcinomas: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 46:3225–3238PubMedGoogle Scholar
  27. Siebert JD, McClure SP, Banks PM, Gulley ML (1995) Hodgkin’s disease, mixed cellularity type, with a B-cell immunophenotype. Report of a case and literature review. Arch Pathol Lab Med 119:474–479PubMedGoogle Scholar
  28. Sigel JE, Hsi ED (2000) Immunohistochemical analysis of CD30-positive lymphoproliferative disorders for expression of CD95 and CD95L. Mod Pathol 13:446–451PubMedCrossRefGoogle Scholar
  29. Sternberger LA, Sternberger NH (1986) The unlabeled antibody method: comparison of peroxidase-antiperoxidase with avidin-biotin complex by a new method of quantification. J Histochem Cytochem 34:599–605PubMedCrossRefGoogle Scholar
  30. Sternberger LA, Hardy PH Jr, Cuculis JJ, Meyer HG (1970) The unlabeled antibody enzyme method of immunohistochemistry: preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes. J Histochem Cytochem 18:315–333PubMedCrossRefGoogle Scholar
  31. van Doorn HC, Burger CW, van der Valk P, Bonfrér HMG (2000) Oestrogen, progesterone, and androgen receptors in ovarian neoplasia: correlation between immunohistochemical and biochemical receptor analyses. J Clin Pathol 53:201–205PubMedCrossRefGoogle Scholar
  32. Webster JD, Miller MA, Dusold D, Ramos-Vara J (2009) Effects of prolonged formalin fixation on diagnostic immunohistochemistry in domestic animals. J Histochem Cytochem 57:753–761PubMedCrossRefGoogle Scholar
  33. Yilmazer D, Han Ü, Önal B (2007) A comparison of the vascular density of VEGF expression with microvascular density determined with CD34 and CD31 staining and conventional prognostic markers in renal cell carcinoma. Int Urol Nephrol 39:691–698PubMedCrossRefGoogle Scholar
  34. Zubovits J, Buzney E, Yu L, Duncan LM (2004) HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma. Hum Pathol 35:217–223PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Pathology, Centre Hospitalier Affilié Universitaire de Québec, Hôpital l’Enfant-JésusFaculty of Medicine, Laval UniversityQuebecCanada

Personalised recommendations